Lessons from the infuse trials: Do we need a classification of bias in scientific publications and editorials?

Current Reviews in Musculoskeletal Medicine

Volumn 7, Issue 3, 2014, Pages 193-199

  Hashmi, Sohaib ^a   Noureldin, Mohamed ^a   Khan, Safdar N ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Adverse events; Bias; Bias classification system; BMP; Infuse trials

Indexed keywords

RECOMBINANT BONE MORPHOGENETIC PROTEIN 2;

ABSENCE OF SIDE EFFECTS; ANTERIOR SPINE FUSION; BONE GRAFT; CLINICAL TRIAL (TOPIC); CONFLICT OF INTEREST; DATA ANALYSIS; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GRAFT FAILURE; HUMAN; INFORMATION PROCESSING; OSTEOLYSIS; PEER REVIEW; PRIORITY JOURNAL; PROSTHESIS INFECTION; PROSTHESIS LOOSENING; PSEUDARTHROSIS; PUBLISHING; RADICULITIS; RETROGRADE EJACULATION; REVIEW; SPINE FUSION; STUDY DESIGN; SYSTEMATIC ERROR; TREATMENT OUTCOME; UROGENITAL TRACT DISEASE;

EID: 84906789981     PISSN: 1935973X     EISSN: 19359748     Source Type: Journal    
DOI: 10.1007/s12178-014-9223-1     Document Type: Review

References (42)

1. Urist MR. Bone: formation by autoinduction. Science. 1965;150:893-9.
2. Grabowski G, Cornett CA. Bone graft and bone graft substitutes in spine surgery: current concepts and controversies. J Am Acad Orthop Surg. 2013;21:51-60. doi:10.5435/jaaos-21-01-51.
3. Boden SD, Zdeblick TA, Sandhu HS, Heim SE. The use of rhBMP-2 in interbody fusion cages. Definitive evidence of osteoinduction in humans: a preliminary report. Spine. 2000;25:376-81. (Pubitemid 30097051)
4. Boden SD, Kang J, Sandhu H, Heller JG. Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial: 2002 Volvo Award in clinical studies. Spine. 2002;27:2662-73. doi:10.1097/01.brs.0000035320.82533.06. (Pubitemid 35425320)
5. Burkus JK, Gornet MF, Dickman CA, Zdeblick TA. Anterior lumbar interbody fusion using rhBMP-2 with tapered interbody cages. J Spinal Disord Tech. 2002;15:337-49.
6. Burkus JK, Transfeldt EE, Kitchel SH, Watkins RG, Balderston RA. Clinical and radiographic outcomes of anterior lumbar interbody fusion using recombinant human bone morphogenetic protein-2. Spine. 2002;27:2396-408. doi:10.1097/01.brs.0000030193.26290.dd. (Pubitemid 35266228)
7. Baskin DS, Ryan P, Sonntag V, Westmark R, Widmayer MA. A prospective, randomized, controlled cervical fusion study using recombinant human bone morphogenetic protein-2 with the CORNERSTONE-SR allograft ring and the ATLANTIS anterior cervical plate. Spine. 2003;28:1219 - 24. doi:10.1097/01.brs. 0000065486.22141.ca. discussion 25.
8. Burkus JK, Heim SE, Gornet MF, Zdeblick TA. Is INFUSE bone graft superior to autograft bone? An integrated analysis of clinical trials using the LT-CAGE lumbar tapered fusion device. J Spinal Disord Tech. 2003;16:113-22.
9. Haid Jr RW, Branch Jr CL, Alexander JT, Burkus JK. Posterior lumbar interbody fusion using recombinant human bone morphogenetic protein type 2 with cylindrical interbody cages. Spine J. 2004;4:527-38. doi:10.1016/j.spinee.2004. 03.025. discussion 38-9.
10. Boakye M, Mummaneni PV, Garrett M, Rodts G, Haid R. Anterior cervical discectomy and fusion involving a polyetheretherketone spacer and bone morphogenetic protein. J Neurosurg Spine. 2005;2:521-5. doi:10.3171/spi.2005.2. 5.0521.
11. Burkus JK, Sandhu HS, Gornet MF, Longley MC. Use of rhBMP-2 in combination with structural cortical allografts: clinical and radiographic outcomes in anterior lumbar spinal surgery. J Bone Joint Surg Am. 2005;87:1205-12. doi:10.2106/jbjs.d.02532.
12. Glassman SD, Dimar III JR, Burkus K, Hardacker JW, Pryor PW, Boden SD, et al. The efficacy of rhBMP-2 for posterolateral lumbar fusion in smokers. Spine. 2007;32:1693 -8. doi:10.1097/BRS.0b013e318074c366.
13. Dawson E, Bae HW, Burkus JK, Stambough JL, Glassman SD. Recombinant human bone morphogenetic protein-2 on an absorbable collagen sponge with an osteoconductive bulking agent in posterolateral arthrodesis with instrumentation. A prospective randomized trial. J Bone Joint Surg Am. 2009;91:1604-13. doi:10.2106/jbjs.g.01157.
14. Dimar II JR, Glassman SD, Burkus JK, Pryor PW, Hardacker JW, Carreon LY. Clinical and radiographic analysis of an optimized rhBMP-2 formulation as an autograft replacement in posterolateral lumbar spine arthrodesis. J Bone Joint Surg Am. 2009;91:1377-86. doi:10.2106/jbjs.h.00200.
15. Spengler DM. Resetting standards for sponsored research: do conflicts influence results? Spine J. 2011;11:492-4. doi:10.1016/j.spinee.2011.05.001. Commentary on Carragee et al "A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned" raises questions regarding state of peer-review process, conflicts of interest, and regulation and use of rhBMP-2.
16. Poynton AR, Lane JM. Safety profile for the clinical use of bone morphogenetic proteins in the spine. Spine. 2002;27(16 Suppl 1):S40-8.
17. Carragee EJ, Hurwitz EL, Weiner BK. A critical review of recombinant human bonemorphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J. 2011;11:471-91. doi:10.1016/j.spinee. 2011.04.023. This article compared data published in the original 13 industry-sponsored rhBMP-2 studies with data provided in the FDAwebsite and spinal literature investigating BMP use concluding that the original industry-sponsored articles systemically aligned to report positive results of BMP use in spinal fusion.
18. Owen R. Reader bias. JAMA. 1982;247:2533-4. doi:10.1001/jama.1982. 03320430037027.
19. Carragee EJ, Ghanayem AJ, Weiner BK, Rothman DJ, Bono CM. A challenge to integrity in spine publications: years of living dangerously with the promotion of bone growth factors. Spine J. 2011;11:463-8. doi:10.1016/j.spinee.2011.06. 001. This editorial states the precedence for critical review and cause of discrepancy between the original industry-sponsored BMP studies compared with later studies reporting higher rate of adverse events with use of BMP.
20. Fu R, Selph S, McDonagh M, Peterson K, Tiwari A, Chou R, et al. Effectiveness and harms of recombinant human bone morphogenetic protein-2 in spine fusion: a systematic review andmeta-analysis. Ann Intern Med. 2013;158:890-902. doi:10.7326/0003-4819-158-12-201306180-00006. This independent systematic review and meta-analysis of 17 industry-sponsored studies and subsequent publications regarding rhBMP-2 use in spine fusion surgery concluded rhBMP-2 has no proven clinical advantage over bone graft and may be associated with important harms, unclear indications for proper use of rhBMP-2, and earlier disclosure of original BMP studies would have better informed clinicians and the public.
21. Mirza SK. Folly of FDA-approval studies for bone morphogenetic protein. Spine J. 2011;11:495-9. doi:10.1016/j.spinee.2011.05.009. This commentary on Carragee et al "A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned" discusses the systematic bias leading to the reporting of highly favorable results in the original industry-sponsored spinal fusion studies with rhBMP-2.
22. Hrobjartsson A, Thomsen AS, Emanuelsson F, Tendal B, Hilden J, Boutron I, et al. Observer bias in randomized clinical trials with measurement scale outcomes: a systematic review of trials with both blinded and nonblinded assessors. CMAJ. 2013;185:E201-11. doi:10.1503/cmaj.120744.
23. Khan SN, Mermer MJ, Myers E, Sandhu HS. The roles of funding source, clinical trial outcome, and quality of reporting in orthopedic surgery literature. Am J Orthop. 2008;37:E205-12. discussion E12.
24. Garattini S, Bertele V. Non-inferiority trials are unethical because they disregard patients' interests. Lancet. 2007;370:1875-7. doi:10.1016/s0140- 6736(07)61604-3. (Pubitemid 350180009)
25. Kaul S, Diamond GA. Good enough: a primer on the analysis and interpretation of noninferiority trials. Ann Intern Med. 2006;145:62-9. (Pubitemid 46780603)
26. Le Henanff A, Giraudeau B, Baron G, Ravaud P. Quality of reporting of noninferiority and equivalence randomized trials. JAMA. 2006;295:1147-51. doi:10.1001/jama.295.10.1147. (Pubitemid 43352344)
27. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA. 1996;276:637-9. (Pubitemid 26278070)
28. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332. doi:10.1136/bmj.c332.
29. Boutron I, Moher D, Tugwell P, Giraudeau B, Poiraudeau S, Nizard R, et al. A checklist to evaluate a report of a nonpharmacological trial (CLEAR NPT) was developed using consensus. J Clin Epidemiol. 2005;58:1233-40. doi:10.1016/j.jclinepi.2005.05.004. (Pubitemid 41608539)
30. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62:1006-12. doi:10.1016/j.jclinepi.2009.06.005.
31. Elm EV, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335:806-8. doi:10.1136/bmj.39335.541782.AD. (Pubitemid 350057266)
32. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008-12. (Pubitemid 30214957)
33. Wright JG, Swiontkowski MF, Heckman JD. Introducing levels of evidence to the journal. J Bone Joint Surg Am. 2003;85-A:1-3. (Pubitemid 36537965)
34. Obremskey WT, Pappas N, Attallah-Wasif E, Tornetta III P, Bhandari M. Level of evidence in orthopaedic journals. J Bone Joint Surg Am. 2005;87:2632-8. doi:10.2106/jbjs.e.00370. (Pubitemid 41747029)
35. Poolman R, Struijs P, Krips R, Sierevelt I, Lutz K, Bhandari M. Does a "Level I Evidence" rating imply high quality of reporting in orthopaedic randomised controlled trials? BMC Med Res Meth. 2006;6:44.
36. Bhandari M, Guyatt GH, Lochner H, Sprague S, Tornetta III P. Application of the Consolidated Standards of Reporting Trials (CONSORT) in the fracture care literature. J Bone Joint Surg Am. 2002;84-A:485-9. (Pubitemid 37107723)
37. Chan S, Bhandari M. The quality of reporting of orthopaedic randomized trials with use of a checklist for nonpharmacological therapies. J Bone Joint Surg Am. 2007;89:1970-8. doi:10.2106/jbjs.f.01591. (Pubitemid 350195028)
38. van Oldenrijk J, van Berkel Y, Kerkhoffs GM, Bhandari M, Poolman RW. Do authors report surgical expertise in open spine surgery related randomized controlled trials? A systematic review on quality of reporting. Spine. 2013;38:857-64. doi:10.1097/BRS.0b013e31827ecb1c.
39. Gelberman RH, Samson D, Mirza SK, Callaghan JJ, Pellegrini Jr VD. Orthopaedic surgeons and the medical device industry: the threat to scientific integrity and the public trust. J Bone Joint Surg Am. 2010;92:765-77. doi:10.2106/jbjs.i.01164.
40. Carragee EJ, Baker RM, Benzel EC, Bigos SJ, Cheng I, Corbin TP, et al. A biologic without guidelines: the YODA project and the future of bone morphogenetic protein-2 research. Spine J. 2012;12:877-80. doi:10.1016/j.spinee. 2012.11.002. This editorial comments on fundamental flaws in existing studies investigating the efficacy and safety involving BMP-2 in spine surgery, including limitations in methodological, operational, and reporting issues.
41. Buerba RA, Fu MC, Grauer JN. Discrepancies in spine surgeon conflict of interest disclosures between a national meeting and physician payment listings on device manufacturer web sites. Spine J. 2013;13:1780-8. doi:10.1016/j.spinee. 2013.05.032. In this comparison of publically available disclosure/payment data, authors concluded discrepancy rates between what spine surgeons disclosed at NASS 2011 and what companies reported for their consultants were high demanding need for more standardized practice in reporting of financial conflict of interests.
42. Shah RV, Albert TJ, Bruegel-Sanchez V, Vaccaro AR, Hilibrand AS, Grauer JN. Industry support and correlation to study outcome for papers published in Spine. Spine. 2005;30:1099-104. discussion 105.